Metastazavusi liga anksciau galjo bti gydyta hormonais.

Prior hormonal therapy for the treatment of metastatic disease was allowed.

Metastazavusi gaubtinės arba tiesiosios žarnos karcinoma (mGTK)
http://www.emea.europa.eu/

Metastatic carcinoma of the colon or rectum (mCRC)
http://www.emea.europa.eu/

Metastazavusi gaubtins arba tiesiosios zarnos karcinoma (mGTK)

Metastatic carcinoma of the colon or rectum (mCRC)

Metastazavusi liga anksčiau galėjo būti gydyta hormonais.
http://www.emea.europa.eu/

Prior hormonal therapy for the treatment of metastatic disease was allowed.
http://www.emea.europa.eu/

DFSP) ar, kuriems yra pasikartojanti ir (ar) metastazavusi DFSP ir kuri negalima operuoti.

with recurrent and/or metastatic DFSP who are not eligible for surgery.

c) derinant su docetakseliu tiems pacientams, kuri metastazavusi liga anksciau chemoterapiniais vaistais negydyta.

c) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.

c) derinant su docetakseliu tiems pacientams, kurių metastazavusi liga anksčiau chemoterapiniais vaistais negydyta.
http://www.emea.europa.eu/

c) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
http://www.emea.europa.eu/

Herceptin taip pat skirta kartu su paklitakseliu arba docetakseliu pacientams, kuri metastazavusi liga dar negydyta chemoterapiniais vaistais.

Herceptin has also been used in combination with paclitaxel or docetaxel for the treatment of patients who have not received chemotherapy for their metastatic disease.

Herceptin taip pat skirta kartu su paklitakseliu arba docetakseliu pacientams, kurių metastazavusi liga dar negydyta chemoterapiniais vaistais.
http://www.emea.europa.eu/

Herceptin has also been used in combination with paclitaxel or docetaxel for the treatment of patients who have not received chemotherapy for their metastatic disease.
http://www.emea.europa.eu/

b) derinant su paklitakseliu tiems pacientams, kuri metastazavusi liga anksciau negydyta chemoterapiniais vaistais ir kuriems antraciklinas netinka.

b) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.

b) derinant su paklitakseliu tiems pacientams, kurių metastazavusi liga anksčiau negydyta chemoterapiniais vaistais ir kuriems antraciklinas netinka.
http://www.emea.europa.eu/

b) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
http://www.emea.europa.eu/

kuriems yra nerezekuotina iškilioji dermatofibrosarkoma (dermatofibrosarcoma protuberans - DFSP) ar, kuriems yra pasikartojanti ir (ar) metastazavusi DFSP ir kurių negalima operuoti.
http://www.emea.europa.eu/

adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/ or metastatic DFSP who are not eligible for surgery.
http://www.emea.europa.eu/

Vaistas skiriamas, kai karcinoma yra nerezekuojama (kai jos negalima pasalinti chirurginiu bdu) , metastazavusi (persimetusi kitas kno dalis) arba recidyvavusi (atsinaujinusi po gydymo) .

It is used when the cancer is unresectable (cannot be removed by surgery) , is metastatic (has spread to other parts of the body) , or has relapsed (returned after treatment) .

Klinikiniai duomenys Klinikini tyrim metu Herceptin vartotas monoterapijai (vien Herceptin) serganci metastazavusiu krties vziu t pacient, kuri navik HER2 raiska buvo padidjusi ir kuri metastazavusi liga kart ar daugiau neskmingai gydyta chemoterapiniais vaistais.

Clinical Data Herceptin has been used in clinical trials as monotherapy for patients with metastatic breast cancer who have tumours that overexpress HER2 and who have failed one or more chemotherapy regimens for their metastatic disease (Herceptin alone) .

2 Metastazavusi gaubtins arba tiesiosios zarnos karcinoma (mGTK)Rekomenduojama Avastin doz lasinti ven yra 5 mg/kg ar 10 mg/kg kno svorio kart kas 2 savaites, arba 7, 5 mg/kg ar 15 mg/kg kno svorio kart kas 3 savaites.

The recommended dose of Avastin, administered as an intravenous infusion, is either 5 mg/kg or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks.

Klinikiniai duomenys Klinikinių tyrimų metu Herceptin vartotas monoterapijai (vien Herceptin) sergančių metastazavusiu krūties vėžiu tų pacientų, kurių navikų HER2 raiška buvo padidėjusi ir kurių metastazavusi liga kartą ar daugiau nesėkmingai gydyta chemoterapiniais vaistais.
http://www.emea.europa.eu/

Clinical Data Herceptin has been used in clinical trials as monotherapy for patients with metastatic breast cancer who have tumours that overexpress HER2 and who have failed one or more chemotherapy regimens for their metastatic disease (Herceptin alone).
http://www.emea.europa.eu/

Pirmuose dviejuose tyrimuose dalyvavo pacientai, kurių metastazavusi liga buvo gydoma pirmą kartą (pirmaeilis gydymas): pirmojo tyrimo metu (kuriame dalyvavo 923 pacientai) buvo lyginamas chemoterapijos veiksmingumas skiriant Avastin ir jo neskiriant, o antrojo tyrimo metu (dalyvavo 1401 pacientas) buvo lyginamas papildomai skirto Avastin ir papildomai skirto placebo (gydomojo poveikio neturinčio preparato) poveikis.
http://www.emea.europa.eu/

The first two studies involved patients whose metastatic disease was being treated for the first time (‘ first-line’ treatment): the first study (923 patients) compared chemotherapy with and without Avastin, and the second (1,401 patients) compared adding Avastin with adding placebo (a dummy treatment).
http://www.emea.europa.eu/